FMP
Exicure, Inc.
XCUR
NASDAQ
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
18.67 USD
2.93 (15.69%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
CIK
0001698530
ISIN
US30205M2008
CUSIP
30205M101
Address
2430 North Halsted Street
Phone
847 673 1700
Country
US
Employee
5
IPO Date
May 22, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
XCUR Financial Summary
CIK
0001698530
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
30205M101
ISIN
US30205M2008
Country
US
Price
18.67
Beta
1.28
Volume Avg.
747.29k
Market Cap
48.65M
Shares
-
52-Week
1.44-36.0
DCF
-0.73
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-9.24
P/B
-
Website
https://www.exicuretx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest XCUR News
It looks like there's no news available.
